Prostate Cancer Trial, Recruiting NCT06273345 Sponsor: Istituto Oncologico Veneto IRCCS Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06273345
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been recently diagnosed with prostate cancer for the first time (any level of risk)
  • People whose prostate cancer has been confirmed through a tissue sample (biopsy), showing a specific type of prostate cancer cell (not a rare type called neuroendocrine)
  • People whose cancer has spread to other parts of the body only to a limited degree — fewer than 4 spots on the bones and no spread to internal organs such as the liver or lungs
  • People who have not previously had surgery or radiation treatment directed at their prostate cancer
  • People who have been on hormone-reducing or other systemic cancer treatment for less than 6 months before joining the trial
  • People who are generally well and able to carry out normal daily activities (rated 0 or 1 on a standard medical fitness scale)
  • People whose doctors consider them suitable for treatment directed at the prostate as well as ongoing whole-body treatment
  • People who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who are unable or unwilling to sign a written consent form
  • People whose cancer has spread widely through the body (high-volume spread, as defined by a standard research guideline called CHAARTED criteria)
  • People who are not well enough to carry out basic daily activities (rated above 1 on the standard medical fitness scale)
  • People who are already participating in another clinical trial
  • People for whom hormone therapy or other systemic treatments are medically not suitable
  • People who have already had surgery, radiation, or any other treatment directed at their prostate tumour

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0423 421321

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istituto Oncologico Veneto IRCCS
Registry
ClinicalTrials.gov
Start date
23 January 2023
Est. completion
1 January 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov